 |
December 15, 2008
Legal Challenge of Big Pharma Extra Monopoly Rights Heads to Court
Long-awaited hearings on extension of “data exclusivity” to be heard in Federal Court tomorrow |
|
| Hearings start tomorrow in the generic pharmaceutical industry’s legal challenge of extended market monopolies for brand-name drugs in the Federal Court of Canada in Toronto. | read more... |
|
December 1, 2008
Fraser Institute Study on Canada/US Drug Prices Uses Flawed Methodology and Data Collection
“Striking similarity” in positions of Fraser Institute and Brand Name Drug Companies |
|
| A report released today by a research team led by Professor Joseph D’Cruz of the Rotman School of Management at the University of Toronto reveals that the methodology and data collection employed by the Fraser Institute in its study Canada’s Drug Price Paradox 2008 does not meet minimum requirements for serious public policy research. | read more... |
|
November 25, 2008
Statement from the Canadian Generic Pharmaceutical Association
Re: Competition Bureau Report on Competition in Generic Drug Sector |
|
| The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the report released today by the Competition Bureau of Canada on competition in the generic drug sector. | read more... |
|
October 9, 2008
Canada’s Generic Drug Makers Ready to Work with All Federal Parties to Enhance Prescription Drug Coverage for Canadians
After 20 Years of Big Pharma’s Broken Promises, Canadians and Their Health-Care System Must Come First |
|
| After reviewing responses to its election survey of federal leaders and the parties’ platforms, the Canadian Generic Pharmaceutical Association (CGPA) said today that prescription drug coverage for Canadians can be improved regardless of the makeup of the next Parliament. | read more... |
|
September 30, 2008
Canada’s Generic Drug Makers Ask Federal Leaders for their Prescription for Drug Coverage |
|
| Canada’s generic pharmaceutical industry is asking leaders of Canada’s political parties for their prescription for improving drug coverage for Canadians, and for helping to get low-cost Canadian-made generic drugs to developing countries. | read more... |
|
July 14, 2008
New Report: Big Pharma Breaks R&D Spending Promise to Canadians for Seventh Consecutive Year
Only two per cent of Canadian sales directed to new medicine discovery |
|
| For the seventh consecutive year, brand-name drug companies have broken their promise to spend at least 10 per cent of their Canadian sales on research and development in Canada, according to the recently released annual report of the Patented Medicine Prices Review Board (PMPRB). The PMPRB report also shows that the brand-name industry spent only two per cent of its Canadian sales on basic research in 2007 that could lead to the discovery of new medicines. | read more... |
|
May 21, 2008
Generic Pharmaceutical Industry Looks Forward to Ongoing Discussions to Enhance PharmaCare for British Columbians |
|
| The Canadian Generic Pharmaceutical Association (CGPA) looks forward to working with the pharmacy community and the Government of British Columbia to develop proposals to increase the generic pharmaceutical industry’s significant contribution to affordable health care, and bring greater transparency to the system. | read more... |
|
May 15, 2008
Spending on Prescription Drugs Slows as Use of Generics Increases: New CIHI Report |
|
| A new report on prescription drug spending in Canada released today by the Canadian Institute for Health Information (CIHI) shows spending on prescription drugs in Canada has slowed as the use of generic medicines has increased, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) said today. | read more... |
|
May 6, 2008
Consumers, Taxpayers to Pay More for Drugs Under
Proposed Changes to Patent Rules
Federal government poised to ignore Supreme Court of Canada and reopen loopholes
that allow for "evergreening" of drug patents |
|
| Proposed amendments to Canada’s drug patent rules will force consumers and taxpayers to pay monopoly drug prices on top-selling prescription drugs for longer than they should by reopening loopholes that allow brand-name drug companies to unfairly keep competition from lower-cost generic prescription medicines off the market. | read more... |
|
April 8, 2008
Generic Pharmaceutical Industry Supports Increased Patient Safety
Health Canada needs tools to monitor prescription drugs after they come to market |
|
| The Canadian Generic Pharmaceutical Association (CGPA) today expressed support for legislative changes to help increase patient safety after new prescriptions drugs are approved in Canada. The CGPA made the comments after Bill C-51 (An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts) was tabled in Parliament earlier today. | read more... |
|
March 26, 2008
Canadians Missing Out on $750-Million in Annual Rx Drug Savings
Gap between use of lower-cost generics in US and Canada widens to nearly 20% |
|
| Canadians could save approximately $750-million on the cost of prescription medicines in the first year alone if the use of generic drugs increased to levels in the United Sates, the Canadian Generic Pharmaceutical Association (CGPA) said today following the release of 2007 Canadian prescription drug sales information by IMS Health Canada. | read more... |
|
March 19, 2008
Canadian Generic Pharmaceutical Association Adopts Code of Marketing Conduct
Effective February 1, 2008 in Quebec and April 1, 2008 in Ontario |
|
| The Canadian Generic Pharmaceutical Association (CGPA) today announced the implementation of its new Code of Marketing Conduct in the Provinces of Quebec and Ontario. | read more... |
|
| < back to news index |
|
TOP |
| |
|
|
